$14.790
+0.275 (+1.86%)收盤時
OBX 同業比較
In the context of the broader market, OBX competes directly with industry leaders such as SVRA and AKTS. With a market capitalization of $860.50M, it holds a significant position in the sector. When comparing efficiency, OBX's gross margin of N/A stands against SVRA's N/A and AKTS's 100.00%. Such benchmarking helps identify whether Obsidian Therapeutics, Inc is trading at a premium or discount relative to its financial performance.
Obsidian Therapeutics, Inc. Common Stock 財務表現
The company is expected to turn profitable by Q4 2025 with a projected net income of $65,358,000, indicating a significant turnaround from current losses.
Financials
FY2026Q1
YoY:
-15.69%
-1.66M
Operating Profit
FY2026Q1
YoY:
+0.88%
-1.61M
Net Income after Tax
FY2026Q1
YoY:
+0.68%
-1.47
EPS - Diluted
FY2025Q4
YoY:
-31.68%
-1.60M
Free Cash Flow
FY2025Q4
2.14K
ROIC
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。